Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Etoricoxib
Primecrown 2010 Limited
M01AH; M01AH05
Etoricoxib
90 milligram(s)
Film-coated tablet
Product subject to prescription which may be renewed (B)
Coxibs; etoricoxib
Authorised
2012-05-04
PACKAGE LEAFLET: INFORMATION FOR THE USER ARCOXIA ® 30 MG FILM-COATED TABLETS ARCOXIA ® 60 MG FILM-COATED TABLETS ARCOXIA ® 90 MG FILM-COATED TABLETS ARCOXIA ® 120 MG FILM-COATED TABLETS etoricoxib READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What ARCOXIA is and what it is used for 2. What you need to know before you take ARCOXIA 3. How to take ARCOXIA 4. Possible side effects 5. How to store ARCOXIA 6. Contents of the pack and other information 1. WHAT ARCOXIA IS AND WHAT IT IS USED FOR WHAT IS ARCOXIA? ARCOXIA contains the active substance etoricoxib. ARCOXIA is one of a group of medicines called selective COX-2 inhibitors. These belong to a family of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). WHAT IS ARCOXIA USED FOR? ARCOXIA helps to reduce the pain and swelling (inflammation) in the joints and muscles of people 16 years of age and older with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and gout. ARCOXIA is also used for the short term treatment of moderate pain after dental surgery in people 16 years of age and older. WHAT IS OSTEOARTHRITIS? Osteoarthritis is a disease of the joints. It results from the gradual breakdown of cartilage that cushions the ends of the bones. This causes swelling (inflammation), pain, tenderness, stiffness and disability. WHAT IS RHEUMATOID ARTHRITIS? Rheumatoid arthritis is a long term inflammatory disease of the joints. It causes pain, stiffness, swelling, and increasing loss of movement in the joints Read the complete document
Health Products Regulatory Authority 23 November 2018 CRN008LM4 Page 1 of 3 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Arcoxia 90 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 90 mg of etoricoxib. Excipient(s) with known effect Lactose monohydrate For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet _Product imported from Portugal and Greece_ White, apple-shaped, biconvex tablets debossed ‘202’ on one side and ‘ARCOXIA 90’ on the other side. 4 CLINICAL PARTICULARS As per PA1997/001/003 5 PHARMACOLOGICAL PROPERTIES As per PA1997/001/003 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Core: Calcium hydrogen phosphate (anhydrous) Croscarmellose sodium Magnesium stearate Microcrystalline cellulose Tablet coating: Carnauba wax Lactose monohydrate Hypromellose Health Products Regulatory Authority 23 November 2018 CRN008LM4 Page 2 of 3 Titanium dioxide (E171) Triacetin 6.2 INCOMPATIBILITIES Not applicable. 6.3 SHELF LIFE The shelf life expiry date of this product shall be the date shown on the blister and outer package of the product on the market in the country of origin. 6.4 SPECIAL PRECAUTIONS FOR STORAGE Store in the original package in order to protect from moisture. 6.5 NATURE AND CONTENTS OF CONTAINER _Product imported from Portugal _ Blisters of 20 or 28 tablets _Product imported from Greece _ Blisters of 14 tablets Not all pack sizes may be marketed. 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL No special requirements. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER Primecrown 2010 Limited 4/5 Northolt Trading Estate Belvue Road Northolt Middlesex UB5 5QS United Kingdom 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA1633/045/003 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Health Products Regulatory Authority 23 November 2018 CRN008LM4 Page 3 of 3 Date of first authorisation: 4 th May 2 Read the complete document